Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> China Pharma Providers
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
China Pharma Providers
Type:
CRO-Discovery
Title:
Shanghai Ambrosia Pharmaceuticals Co Ltd
Chinese
CSertification:
n/a
International
Certification:
n/a
Primary Location:
Shanghai
China
Contact Info:
n/a
Webpage:
www.shapb.com
HQ
Contact Info:
Building 8, 439 Chunxiao Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203, China
Tel: +86 21 5080 0885 Fax: +86 21 5080 0306
Email: webmaster@shapb.com
Additional
Contact Info:
n/a
Description:
Shanghai Ambrosia has established a series of disease-targeting screening platforms using the principles of genomic, molecular, cellular and systemic studies. These platforms directly applied the most up-to-date technology in studying regulation of the signal transduction and gene expression in the control of cellular growth, proliferation and death, and are uniquely designed to identify drug candidates from the Traditional Chinese Medicine. These platforms provide a multi-level selection system to identify drug candidates and dietary supplement targeting cancer, allergy, auto-immune diseases, neurodegenerative diseases and aging.
Shanghai Ambrosia is a privately owned biopharmaceutical company dedicated to the discovery and development of novel therapeutics and health products for the treatment of immune diseases and cancer. The Shanghai Ambrosia was established in 2002 at the Pudong Zhangjiang High Tech Park by a group of world-renowned scientists from Harvard University, Johns Hopkins University, Indiana University and Boston University, experts of pharmaceuticals in America, as well as scientists from the Chinese Academy of Sciences and Tsinghua University. The Shanghai Ambrosia is financed jointly by the Shanghai Venture Ltd. and Shenzhen Qian Long Industrial Co Ltd.
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit